5 completed, 1 withdrawn. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow ASP8062: new trials by email Literature Review of ASP8062 trials Research Report on ASP8062
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Human Laboratory Study of ASP8062 for Alcohol Use Disorder ASP8062, Placebo - Alcohol Use Disorder, Alcohol Drinking | Phase 2 | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 60 | 2021-12-13 | 2024-12-03 |
| A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder ASP8062, Placebo ASP8062, buprenorphine/naloxone - Opioid Use Disorder | Phase 2 | Withdrawn | Astellas Pharma Global Development, Inc. | 2021-11-08 | 2024-11-06 | |
| A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder ASP8062, Placebo ASP8062, buprenorphine/naloxone - Opioid Use Disorder | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 23 | 2020-06-29 | 2024-11-21 |
| A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects ASP8062, Alcohol, ASP8062 Placebo - Healthy Volunteers | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 20 | 2019-07-16 | 2024-11-05 |
| Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects ASP8062, Placebo - Healthy Volunteers | Phase 1 | Completed | Astellas Pharma Inc | 36 | 2017-06-20 | 2024-10-21 |
| A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia ASP8062, Placebo - Fibromyalgia | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 183 | 2017-05-08 | 2025-11-03 |
Opioid-Related Disorders (2) · Alcohol Drinking (1) · Alcoholism (1) · Fibromyalgia (1)
Astellas Pharma Global Development, Inc. (4) · Astellas Pharma Inc (1) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1)
United States (4) · Japan (1)
UG3DA051392 (1)